Share on StockTwits

Zeltiq Aesthetics (NASDAQ:ZLTQ) VP Carl Lamm sold 1,807 shares of the stock on the open market in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $21.36, for a total transaction of $38,597.52. Following the transaction, the vice president now directly owns 24,724 shares of the company’s stock, valued at approximately $528,105. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ZLTQ has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday, July 31st. Analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $25.00.

Zeltiq Aesthetics (NASDAQ:ZLTQ) traded up 0.35% during mid-day trading on Wednesday, hitting $23.24. 682,008 shares of the company’s stock traded hands. Zeltiq Aesthetics has a 52 week low of $7.96 and a 52 week high of $24.79. The stock has a 50-day moving average of $18.97 and a 200-day moving average of $17.7. The company’s market cap is $872.1 million.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its earnings data on Tuesday, July 29th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. The company’s quarterly revenue was up 79.1% on a year-over-year basis. Analysts expect that Zeltiq Aesthetics will post $-0.18 EPS for the current fiscal year.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.